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ABSTRACT
BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR THE MANAGEMENT OF
MODERATE-TO-SEVERE ATOPIC DERMATITIS IN PATIENTS TREATED WITH
SYSTEMIC THERAPIES IN THE UNITED STATES
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

By: Haya Alobaid
Director: David A. Holdford, RPh, MS, PhD, FAPhA

Objective: This study evaluated the budget impact of introducing upadacitinib for patients with
uncontrolled moderate-to-severe atopic dermatitis (AD) from a United States (U.S.) private
payer perspective.
Methods: The model estimated costs before and after the adoption of upadacitinib for a
hypothetical one million covered lives over 3 years. The model included immunosuppressant
agents and dupilumab. Market uptake was assumed to be 2% per year. Treatments incur a cost
for drug acquisition, and the costs associated with drug administration, laboratory testing, and
clinic visits. The model calculated the impact on the budget in 2022 U.S. dollars. Various
assumptions on market uptake were analyzed, and a sensitivity analysis was performed.
Results: For one million covered lives with an estimated 3607 people receiving
immunosuppressant agents or dupilumab, the total cost after introducing upadacitinib increased
by $3.5, $7.0, and $10.5 million in years 1–3, respectively, resulting in a cumulative increase of
$21.1 million over 3 years. The incremental per member per year costs were $3.52, $7.04, and
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$10.59 in years 1–3, respectively, resulting in an increase in per member per month costs of
$0.29 in year 1, $0.59 in year 2, and $0.88 in year 3. The incremental per treated member per
month costs were $70.77, $140.72, and $210.67 in years 1–3, respectively. Scenario and
sensitivity analyses confirmed the model robustness.
Conclusions: The introduction of upadacitinib had a high impact on the U.S. private payer
budget. The use of upadacitinib may increase the cost of treating patients with uncontrolled
moderate-to-severe AD.
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CHAPTER 1. INTRODUCTION AND BACKGROUND
Atopic dermatitis (AD), also known as eczema, is a chronic or relapsing inflammatory skin
disease.1 It is characterized by skin barrier disruption and immune dysregulation largely
mediated by type 2 helper T cells.1 An AD-affected individual may suffer from skin irritation,
inflammation, and pruritus, and the disease typically has flares and remissions that occur
intermittently, often for unexplained reasons.2 AD is a multifactorial disease that is influenced by
genetics, immune, and environmental factors.3 There is controversy over whether AD is
predominantly caused by barrier dysfunction (outside–in hypothesis) or by an inflammatory
response to environmental allergens and irritants (inside–out hypothesis).4 The "outside-in"
hypothesis suggests that AD is preceded by impaired epidermal barrier function and thus
requires it for disease to manifest.5 Filaggrin gene (FLG) mutations that result in loss-of-function
are indicative of this hypothesis.5 The FLG gene dysfunction can lead to poor epidermal barrier
function, which increases water loss and makes the skin more prone to foreign substances that
could result in inflammation in the skin and systemically, and thus, can lead to atopic diseases,
for example, asthma and food allergy.5 The "inside-out" hypothesis implies that inflammation
occurs before and even contributes to AD barrier dysfunction.6 This hypothesis implies that AD
might be linked to variants in genes primarily involved in immune pathways, such as interleukin
(IL)-4R, IL-18, and IL-31.6 It also has been suggested that environmental exposures may trigger
and/or flare AD disease among predisposed individuals.3 Different environmental factors play an
interdependent role in AD disease, including individual usage of personal care products and
exposure to climate, pollution, and food.3
AD most often starts in childhood; more often than not, it occurs between 3 and 6
months, though it may occur at any age.7 The risk of developing AD is much higher in those who

12

have a family or personal history of other atopic disorders such as asthma or allergic rhinitis.8
Because of the chronic nature of this disease, as well as its relapsing nature, it can be associated
with a substantial or multidimensional patient burden.9 This is especially true in moderate-tosevere patients, who may have increased atopic comorbidities (asthma, nasal, and food
allergies10), neuropsychiatric conditions (sleep disturbance11, anxiety, and depression12), and
impaired quality of life (QoL).13 Furthermore, moderate-to-severe AD patients with inadequate
disease control report even higher patient-reported burden, including anxiety, depression, sleep
disturbance, and impaired QoL, than patients with controlled disease.14
In the United States (U.S.), it is estimated that the prevalence of AD is 10.7% among
children under 18 years of age and 7.3% among adults.15,16 Although AD is often considered a
childhood disease, recent evidence suggests that it is more common in adults than previously
recognized.17 According to a recent population-based estimate for adults, a total of 16.5 million
have AD in the U.S., of which 6.6 million (40%) report moderate-to-severe symptoms.16 The
prevalence of AD in adult females (11.1%) is higher than males (9.1%),18 and the prevalence of
AD in African American children (19.3%) is higher than European American children (16.1%).19
Currently, there is no consensus regarding the diagnostic testing that should be performed
on AD patients.20 Diagnostic approaches for AD vary widely due to the lack of reliable
biomarkers that can distinguish AD from other skin diseases.20 Therefore, the diagnosis for AD
is based on a constellation of clinical features, morphology, and distribution of skin lesions, and
associated clinical signs and symptoms.20 In some cases, skin biopsy specimens or other tests,
including total and/or allergen-specific serum Immunoglobulin (Ig)E, and/or genetic tests, may
help to rule out other skin conditions.20
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The AD severity assessment helps guide clinical decision-making and is evaluated in
clinical trials by various tools including, the Eczema Area and Severity Index (EASI) score, the
SCORing AD (SCORAD) index, and the Patient-Oriented Eczema Measure (POEM) severity
score.20,21 The EASI score is a simple tool that measures the extent (area) and severity of AD.22
In EASI scoring, patients are categorized as follows: 0 = clear; 0.1-1.0 = almost clear; 1.1-7.0 =
mild; 7.1-21.0 = moderate; 21.1-50.0 = severe; 50.1-72.0 = very severe.22 The SCORAD index is
a clinical tool used to assess AD severity based on area affected, intensity (redness, swelling,
oozing, scratch marks, skin thickening, and dryness), and subjective symptoms (itchiness and
sleeplessness).23 Based on the SCORAD index, the severity of AD can be classified into mild
(<15), moderate (between 15 and 40), and severe (≥40).24 The POEM scale is a tool used to
monitor AD severity by evaluating whether time spent with AD symptoms (itching, bleeding,
flaking, weeping or oozing clear fluid, cracked skin, dry skin) interferes with sleep during the
past week.25 The POEM scores are categorized into five severity bands as follows: POEM scores
of 0–2 = clear/almost clear; 3–7 = mild; 8–16 = moderate; 17–24 = severe; 25–28 = very severe
AD.25 American Academy of Dermatology (AAD) guidelines do not recommend the use of
disease severity scales for clinical practice and suggest only that they be used in clinical trials.20
In clinical practice, they recommend that severity of AD be classified according to a patient’s
physical symptoms, the amount of body surface area affected, the location of the rash, and the
condition’s impact on sleep and QoL.26 If the patient has not responded to treatment, then the AD
severity assessment should be re-evaluated.20
AD is an incurable condition. The treatment focuses on reducing the number of
exacerbations or flares, as well as the duration and severity of flares if they do occur, improving
the skin’s barrier function, suppressing inflammation, and relieving pruritus.27 All AD patients,
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regardless of the severity of their disease, should follow a routine of proper skin care,
moisturizers, antiseptic measures, and avoiding triggers at all times.28 Patients who can be
controlled with non-pharmacological management often have mild disease, whereas when their
symptoms cannot be adequately controlled with non-pharmacological therapies, they are
considered to have moderate-to-severe disease.28 The AAD29 and the American Academy of
Allergy, Asthma, & Immunology (AAAAI)30 recommend the use of proactive maintenance
topical anti-inflammatory medications such as topical corticosteroids (TCSs) or topical
calcineurin inhibitors (TCIs) as an additional treatments to the non-pharmacological management
for moderate-to-severe AD patients. For acute treatment of flares in moderate-to-severe AD
patients, TCSs or TCIs have to be applied consistently in flare-prone areas and at the first sign of
a flare.29 Acute flares for moderate-to-severe AD patients may be treated with medium potency
or low potency TCSs based on patients' and providers' preferences.29 TCSs have been used for
more than 60 years to treat AD, as both an active inflammatory disease as well as a prevention of
relapse, except on areas of thin or sensitive skin.29 However, treatment adherence concerns with
the use of TCSs can be negatively impacted by the fear of TCSs withdrawal and side effects.31,32
TCIs, tacrolimus ointment and pimecrolimus cream, are newer formulations that are effective for
both chronic inflammation and acute flare-ups of AD, and they have particular use on thin or
sensitive skin sites.29,33 Despite this, there are a number of adverse reactions associated with
TCIs use, including transient burning sensations, pruritus, and erythema.34 Additionally, TCIs
carry a "black box" warning that indicates a potential risk of malignancy, though many clinical
experts question the validity of the warning.35 Crisaborole 2% ointment is an anti-inflammatory
non-steroidal topical treatment option for AD patients with mild to moderate disease.36 Although
crisaborole 2% is considered safe, burning/stinging can occur at or near the application site.36
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Patients with moderate-to-severe disease who do not respond to the maintenance topical
anti-inflammatory medications may benefit from second-line treatments such as phototherapy or
systemic medications.37 Prior to starting the second-line treatment, it is important to assess these
patients for nonadherence, comorbidity, and other factors that might negatively influence the
response to previous therapy.38 In adults with recalcitrant eczema, narrow band Ultraviolet-B
(nbUVB) phototherapy can be particularly beneficial for treating widespread eczema.39 The
nbUVB penetrates the skin and affects the immune system by reducing inflammation. 39
Phototherapy, however, leads to premature aging of the skin and increases the risk of skin cancer
overtime, and for this reason, it is suggested to be used cautiously.39 In terms of cost,
convenience, and accessibility, the patient should be willing and able to commit to
phototherapy.38 Treatment with systemic immunosuppressant agents, such as corticosteroids,
azathioprine, methotrexate, mycophenolate mofetil, and cyclosporine A, are indicated for very
severe, chronic, relapsing AD in patients whose optimized topical anti-inflammatory regimens
do not provide adequate relief from symptoms.39 Such treatments are off-label in the U.S. and
generally limited for patients with moderate-to-severe AD who do not respond to topical antiinflammatory medications.39 Efficacy and safety of these treatments are limited, and there are
few studies in the literature that compare them to one another.39 According to the AAD
guidelines, systemic corticosteroids, such as prednisone, should be avoided if possible for the
treatment of moderate-to-severe AD, and maintenance treatment with oral corticosteroids is not
recommended for serious AD.39 These drugs should be reserved exclusively for treating acute,
severe exacerbations and for transitioning to other systemic, steroid-free therapies.39 Patients
with AD may be treated with oral antihistamines to reduce pruritus and improve their QoL, but
there is insufficient evidence to recommend general use of antihistamines as a treatment
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approach.39,40 There are several serious side effects associated with systemic
immunosuppressants, including increased risk of infections, increased risk for certain types of
cancers, increased risk of kidney damage with cyclosporine A and methotrexate, increased blood
pressure with cyclosporine A and corticosteroids.39,41 As of that, they require close initial
laboratory testing and/or ongoing laboratory monitoring.39,41 Current guidelines discourage
general use of systemic immunosuppressant agents including oral corticosteroids. 30,39
Yet, while most patients are able to improve their symptoms or control them with
traditional treatments, some do experience treatment failure, including a decrease in QoL,
inadequate clinical improvement, or failure to achieve long-term control.42 AD has been shown
to affect the U.S. economy in many ways. A conservative estimate of the economic cost of AD,
including direct medical costs, indirect costs from lost productivity, and QoL impacts, is $5.3
billion annually in 2015.43 Evidence from the 2013 U.S. National Health and Wellness Survey
indicates that the annual per patient total direct, emergency department visits, hospitalization,
healthcare provider visits costs for AD patients are significantly higher than their non-AD
counterparts.10 AD patients have higher out-of-pocket health care costs than those without the
disease, and the out-of-pocket health care costs for AD per person per year ($371-$489) was
higher than the out-of-pocket costs for hypertension ($206-$241) and diabetes mellitus ($353$210).44 Patients with AD disease have a considerably higher absenteeism and activity
impairment rate compared to those without.45 In some cases, disease flares can impact 15% of a
workday of those who have the disease, which incur a considerable indirect medical cost.46
Approximately 55% of adults with AD report inadequate disease control.14 This suggests the
need for better treatment options for AD patients, especially those suffering with uncontrolled
moderate-to-severe symptoms.
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In light of this significant economic impact, the number of options for treating moderateto-severe AD patients with uncontrolled symptoms has resulted in the approval of several new
classes of medications for those patients.47 As of March 2017, the U.S. Food and Drug
Administration (FDA) approved dupilumab, a human monoclonal IgG4 antibody, for the
treatment of patients aged 6 years and older with moderate-to-severe AD.48 The approval was for
use in uncontrolled AD or when other therapies are not advisable, becoming the first biologic
agent registered for the treatment of this chronic skin condition.48 Dupilumab can be used with or
without TCSs or TCIs for moderate-to-severe AD patients with inadequate response.49 IL-4
receptor-a is targeted by dupilumab, effectively inhibiting the signaling of IL-4 and IL-13, which
reduces symptoms and signs of this diseases.49,50 Dupilumab is licensed in the U.S. for
subcutaneous (SC) administration, and so far, it is considered a safe treatment option for
moderate-to-severe AD who do not respond to topical anti-inflammatory medications.51
Dupilumab has no recognized short term or serious side effects including injection site reactions
and eyelid inflammation. Thus, it does not require initial laboratory testing or ongoing laboratory
monitoring.51 In spite of dupilumab 's novel therapeutic approach, it may not be appropriate for
all patients with AD because of the SC administration and the unique immunophenotype of AD
disease.52 Therefore, there is a need for a broader range of treatment options for this condition,
particularly oral medications, that can provide improved clinical responses for moderate-tosevere AD patients with inadequate response. Figure 1 presents a summary of patient profiles
and current treatment options for the moderate-to-severe atopic dermatitis patients with
inadequate response to topical anti-inflammatory medications.
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Figure 1. Patient Profiles and Recommendations for the Treatment of Moderate-to-Severe Atopic
Dermatitis Patients with Inadequate Response to Topical Medications53

Inadequately controlled signs and symptoms of AD despite an aggressive course of topical therapies (TCIs,
TCSs, or crisaborole 2%) for 3-weeks or more and following basic management recommendations a

The patient should be referred to an allergist or dermatologist b
These patients may need systemic treatment, such as dupilumab c, systemic immunosuppressant agents, or
phototherapy d

Acute treatment of flares:

Maintenance treatments:
e

e

Cyclosporine A , methotrexate ,

Topical anti-inflammatory medications

mycophenolate mofetil e, azathioprine e,

applied to inflamed skin: g

corticosteroids f

Medium potency TCSs (class III–IV) h

OR

OR

Phototherapy

Low potency TCSs (class V–VII) h

OR

OR

Dupilumab

TCIs (pimecrolimus or tacrolimus) I

AD, atopic dermatitis; TCIs, topical calcineurin inhibitors; TCSs, topical corticosteroids
a
Basic management includes skin care and antiseptic measures, trigger avoidance, and, specifically, when the
condition significantly impacts daily activities, psychological health, and quality of life.38
b
It is important to evaluate the patient for nonadherence, comorbidity, and other factors that might negatively affect
response of previous therapy.38
c
Indicated for patients aged 6 years and older with moderate-to-severe AD whose disease is not adequately
controlled with topical anti-inflammatory medications or when those therapies are not advisable. 48
d
Beneficial for treating widespread eczema.39
e
Not approved by the Food and Drug Administration to treat moderate-to-severe AD.39
f
Approved by the Food and Drug Administration to treat AD, but not recommended for long-term maintenance.39
g
Useful for flares (depending on severity of the flare and provider/patient’s preference; not indicated dosage).39
h
Except for face and/or eyes.39
I
Include face and/or eyes.39
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There are currently other biologic therapies being developed for treating AD, including
omalizumab, lebrikizumab, and tralokinumab.54 Unlike antibody-based therapies, which are
usually targeting cytokines or their receptors, small molecules are newer therapies being
developed to interfere with intracellular signaling pathways.54 Janus kinase (JAK) inhibitors
constitute the largest group of these molecules.54 Oral JAK inhibitors, such as upadacitinib,
baricitinib, and apremilast, could provide effective treatment option for moderate-to-severe AD
given their rapid onset of action.54 As of January 2022, The U.S. FDA approved upadacitinib for
the treatment of moderate-to-severe AD in adults and children 12 years of age and older whose
disease did not respond to previous treatment and is not well controlled with other pills or
injections, including biologic medications, or when use of other pills or injections is not
recommended.55 Upadacitinib is currently approved by the European Commission (EC) for the
treatment of moderate-to-severe AD in patients who are candidates for systemic therapy.56
Upadacitinib is a selective JAK inhibitor, which is designed to have increased selectivity for
JAK1 over JAK2, JAK3, and tyrosine kinase 2.57 Upadacitinib side effect profile indicates that
infections are more common and certain laboratory parameters are altered during treatment,
including elevated liver function values, blood count changes, and elevated creatine kinase
values, and thus, this treatment requires more intensive patient monitoring.58 In addition, a black
box warning has been added by the FDA on all approved JAK inhibitors in September 2021
regarding serious heart-related events such as heart attack, stroke, cancer, blood clots, and
death.59 Several randomized-controlled trials showed that upadacitinib (once-daily/15 or 30 mg)
is a well-tolerated and effective treatment option for patients with moderate-to-severe AD.60,61 In
addition, a recent randomized-controlled trial showed that upadacitinib (30 mg once daily,
orally) is well tolerated and is more effective than dupilumab (300 mg every other week, SC) for
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moderate-to-severe AD adult patients after 16 weeks of treatment.62 Therefore, upadacitinib
could offer a viable treatment alternative to current systemic therapies for adult patients with
moderate-to-severe AD who do not respond to topical anti-inflammatory medications.
Since treating moderate-to-severe AD patients can be costly, researchers have been
performing economic evaluations of these breakthrough treatments with the current or standard
of care.63–65 In August 2021, the Institution for Clinical and Economic Review (ICER) published
a report evaluating the clinical effectiveness and value of new therapies indicated for AD,
including upadacitinib.65 By performing a cost-effectiveness analysis (CEA) comparing
upadacitinib for moderate-to-severe AD to the standard of care (topical medications) and
dupilumab, over a five-year time horizon, the incremental CEA base case results were
$1,912,200 per quality-adjusted life year (QALY) for upadacitinib and dupilumab, and $248,400
per QALY for upadacitinib and the standard of care. The report also stated that the estimated
health-benefit price benchmark (HBPB), a commonly cited cost-effectiveness threshold between
$100,000 and $150,000 per QALY gained, is $30,400-$41,500 per year for upadacitinib, which
would require a 35-53% discount off the treatment's current U.S. list price of $64,300 to reach
common threshold of cost-effectiveness.65
To this direction, the concept of budget impact analysis can be of significant benefit as
payers are still struggling to deal with the escalating cost of new treatments to treat patients with
uncontrolled moderate-to-severe AD.38 In addition, there is also no certainty about how the
adoption of upadacitinib will affect formulary budgets for U.S. private payers. The objective of
this study is to estimate the incremental budgetary impact of the introduction of upadacitinib for
patients with moderate-to-severe AD whose disease is not adequately controlled with topical
anti-inflammatory medications from a U.S. private payer perspective.
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CHAPTER 2. METHODS
2.1 Model Structure
A flexible budget impact model based on Microsoft Excel was developed from a U.S. private
payer perspective to estimate the expected costs to be incurred by the payer of introducing
upadacitinib over a 3-year time horizon. Because of the perspective of the model, it does not
account for the cost of non-insured moderate-to-severe AD patients.
The model started with a hypothetical one million covered lives and then estimated the
number of eligible patients for upadacitinib using publicly available data. The treated population
size remained constant each year for the model estimate. Moderate-to-severe AD patients whom
are eligible for upadacitinib were divided into subgroups based on the current systemic treatment
options available in the AAD39 & AAAAI30 guidelines, which include immunosuppressant
agents (cyclosporine A, methotrexate, mycophenolate mofetil, and azathioprine), and the only
FDA-approved biological therapy (dupilumab). Despite the FDA's approval for oral
corticosteroids, they are not recommended for patients with moderate-to-severe AD who need
long-term maintenance treatment, so they were not included in the model.29 We thereafter
estimated the annual number of patients treated with each immunosuppressant agent and
dupilumab, as well as the number of patients new to treatment each year. We estimated the
annual number of patients who receive upadacitinib according to the annual market uptake and
the market shares of available treatment options. The current market shares were based on
different market estimates for each immunosuppressant agent and dupilumab. Data on
immunosuppressant market shares are not available publicly. For our estimation, however, a
study that analyzed retrospective claims data regarding the treatment patterns among patients
with AD in the U.S. was used.66 The study was conducted using the IQVIA Health Plan Claims
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that includes patients who newly initiated a treatment for moderate-to-severe AD.66 The vast
majority of patients were 18 years of age or older and commercially insured.66 The market share
for dupilumab was estimated using a report published by the Transparency Market Research
(TMR) regarding key market dynamics and the exponential growth of biological drugs for AD.67
To estimate the budget impact of adding upadacitinib to the treatment mix, two market
scenarios were compared. In the current environment (scenario 1), patients received current
immunosuppressants agents (cyclosporine A, methotrexate, mycophenolate mofetil, and
azathioprine) and dupilumab based on the current market share, and in the new environment
(scenario 2), patients received upadacitinib (introduced to the formulary over 3 years) and all
other immunosuppressants agents, as well as dupilumab, based on projected annual market
shares.
Patients received treatments based on dosing per the prescribing information or
recommended doses suggested by clinical trials, and incurred costs related to treatment
acquisition, treatment administration, laboratory testing/procedure, and clinic visits. As the
model calculations utilized annual cycles, it was assumed that patients receiving treatment would
receive the same treatment for the entire year, and treatment discontinuation was not explicitly
modelled. Costs related to treatment acquisition, treatment administration, laboratory
testing/procedure, and clinic visits were calculated in each market scenario for each year of the
time horizon.
The budget impact was calculated by comparing the total annual costs in scenario 2 with
those in scenario 1. Results were reported in total annual, cumulative, per member per year
(PMPY), per member per month (PMPM), and per treated member per month (PTMPM) costs.
Model-building was done in accordance with guidelines and recommendations issued by the
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International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 68 No
discounting was undertaken pursuant to these guidelines.68 Figure 2 presents the budget impact
model structure.

Figure 2. Budget Impact Model Structure a
Population
(Covered by private health insurance)
Prevalence of atopic dermatitis in adults

Total Patients
(Adults with atopic dermatitis)
% Of adult patients with moderate-tosevere atopic dermatitis

Target Population
(Adults with moderate-tosevere atopic dermatitis)

% Of patients treated with
biological therapy

% Of patients treated with
immunosuppressant agents

Subgroup
(Treated with
immunosuppressant agents)

Subgroup
(Treated with biological
therapy; dupilumab)

Cyclosporine A
Mycophenolate
mofetil
Azathioprine
Methotrexate

% Of patients treated with each
agent

Without upadacitinib

With upadacitinib

Current environment
(Products market share)

New environment
(Products market share)

Current environment
(Total costs)
Treatment acquisition
Treatment administration
Laboratory testing/procedure
Clinic visits

New environment
(Total costs)
Treatment acquisition
Treatment administration
Laboratory testing/procedure
Clinic visits

Budget impact (difference)
a

Model structure was developed in accordance with guidelines and recommendations issued by the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR). 68
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2.2 Population
The modelled patient population was the population indicated for upadacitinib (i.e., adult
patients 18-65 years of age with moderate-to-severe AD whose disease is not adequately
controlled with topical anti-inflammatory medications). The model only includes patients over
18 years of age because upadacitinib trials enrolled a relatively small number of patients under
18 and there is still uncertainty for using this treatment for adolescents.58,60–62
For model building, a one million covered lives were assumed. The number of patients
eligible for treatment was calculated from the U.S. prevalence estimates for adults’ patients with
AD and moderate-to-severe AD.16,69 Among all adult patients with moderate-to-severe AD, 5%
were assumed to be treated with systemic immunosuppressant agents, and 13.4% with the
biological therapy, dupilumab. Of the 5% of patients treated with immunosuppressant agents, it
was assumed that 30.3%, 16.2%, 6.1%, and 47.5% were treated with cyclosporine A,
mycophenolate mofetil, azathioprine, and methotrexate, respectively, based on a study that
analyzed retrospective claims database.66 According to the study, the remaining patients received
systemic oral corticosteroids (73.4%) and phototherapy (8.2%).66 Among patients treated with
immunosuppressant agents and the biological therapy dupilumab, 0.68% were assumed to be
new to treatment each year due to the incidence (1.7%) and the prevalence (40%) of moderateto-severe AD among adults.16,70 In all subsequent years of the model, the portion of upadacitinib
patients new to treatment was consistent with the other modelled treatments (0.68%). The
number of new patients with moderate-to-severe AD were assumed to be new to treatment each
year of the time horizon and 66.50% of those would be covered by the private health insurance.71
The prevalence of moderate-to-severe AD was assumed to remain constant. All-cause mortality
for the modelled population was not considered. The treated population was therefore assumed to
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remain constant over the modelled time horizon. Table 1 provides moderate-to-severe atopic
dermatitis population estimates.

Table 1. Moderate-to-Severe Atopic Dermatitis Population Estimates
Population characteristic

Base case
%

Base case
N

100%

1,000,000

4.9%

49,000

40%

19,600

18.4%

3,606

5%

982

30.3%

297

16.2%

159

6.1%

60

47.5%

466

13.4%

2,626

0.68%

25

0.45%

16

Patients living with moderate-to-severe atopic dermatitis
Total population (18-64 years) covered by private health insurance a
The prevalence of adults with atopic dermatitis

b

With moderate-to-severe atopic dermatitis (eligible for upadacitinib)

c

Eligible patients treated with immunosuppressant agents and dupilumab
Proportion treated with immunosuppressant agents

d, e

Treated with cyclosporine A f
Treated with mycophenolate mofetil
Treated with azathioprine

f

f

Treated with methotrexate

f

Proportion treated with biological therapy/dupilumab d
New immunosuppressant agents or biological therapy/dupilumab users
Proportion of new moderate-to-severe atopic dermatitis patients each year g
Proportion covered by private health insurance
a

h

Hypothetical one million covered lives were assumed.
Point prevalence of atopic dermatitis in adults in the United States was estimated at 4.9%.69
c
It was assumed that 40% of atopic dermatitis patients have moderate-to-severe symptoms.16
d
It was assumed that 5% and 13.4% of patients with moderate-to-severe atopic dermatitis received systemic
immunosuppressants agents and dupilumab, respectively, based on a study that analyzed retrospective claims
database.66
e
Our estimates were based on a study that analyzed retrospective claims database that provided rounded decimal
point proportions. Thus, there were an additional two immunosuppressant agent users.66
f
It was assumed that 30.3%, 16.2%, 6.1%, 47.5% of patients using immunosuppressant agents received
cyclosporine A, mycophenolate mofetil, azathioprine, and methotrexate, respectively, based on a study that analyzed
retrospective claims database.66
g
Based on a prospective cohort study; the incidence of atopic dermatitis was estimated at 1.7%. It was assumed that
0.68% of those had moderate-to-severe atopic dermatitis based on the previous prevalence estimates of 40%.16,70
h
It was assumed that 66.5% of the new patients would be covered by the private health insurance, and of those,
0.45% would be the proportion of new patients each year and covered by the private health insurance.71
b
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2.3 Market Shares
Current market shares before the introduction of upadacitinib (scenario 1) were based on
different market estimates for each immunosuppressant agent and dupilumab. Market shares data
for immunosuppressant agent are not publicly available. However, market shares for
immunosuppressants agents were estimated based on a study that analyzed retrospective claims
data on AD treatment patterns.66 According to the study, methotrexate was the most common
used immunosuppressant agent for the treatment of moderate-to-severe AD (47.5%), followed by
cyclosporine A (30.3%), mycophenolate mofetil (16.2%), and azathioprine (6.1%). Therefore,
methotrexate was assumed to hold a percentage share of 20% as it has been used as a first option
agent among all immunosuppressant agents, cyclosporine A held a percentage share of 10% as a
second option agent, and mycophenolate mofetil and azathioprine held a percentage share of 5%
due to their limited data and clinical use in AD patients. Market share for dupilumab was
estimated based on a published report regarding the exponential growth of biologic drugs for
AD.67 The report stated that biological treatments accounted for the highest market share of 42%
in 2018 and continue to increase to a projected value of 77% in 2027.67 The annual increase in
market share between 2018 and 2027 is 3.8%.67 From 2018 to 2022, a share of approximately
3.8% was added each year to calculate a share of 60% for dupilumab. Moreover, based on a
study reporting the treatment pattern for AD patients, dupilumab (13.4%) has been used more
than all the immunosuppressant agents (5%), and thus, higher market share compared to all
immunosuppressant agents.66 In scenario 2, a 2% annual market uptake for upadacitinib was
assumed over 3 years. Upadacitinib market share was assumed to be taken proportionally from
the other treatments so that the distribution of market shares across the other treatments remained
the same as that in the current market. Annual market shares were multiplied by the total number
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of patients treated each year to determine the number of patients receiving upadacitinib. Market
shares were applied for the entire year, as patients did not switch or discontinue treatment during
the year. Since market share data are not yet publicly available, the estimates used in this model
may not reflect the actual market share of those treatments. Table 2 provides the market share
estimates over the 3-year budget plan.

Table 2. Market Share Estimates Over the 3-year Budget Plan a
Treatment

Current year
10%

Cyclosporine A

9.8%

20%

19.6%

Mycophenolate mofetil

5%

Azathioprine

1.2%
4.7%

0.2%
4.8%

0.3%
4.7%

0.1%
58.8%

Upadacitinib
0%
Market shares of immunosuppressant agents
100%
and dupilumab
Market share of upadacitinib
0%
a
2% annual uptake for upadacitinib was assumed over 3 years.

18.8%

4.8%

0%
60%

0.6%

0.8%

0.1%
4.9%

Upadacitinib
Dupilumab

19.2%

0%
5%

0.4%

0.4%
4.9%

Upadacitinib

Year-3
9.4%

0.2%

0%

Upadacitinib

Year-2
9.6%

0%

Upadacitinib
Methotrexate

Year-1

0.2%
57.6%

1.2%

0.3%
56.4%

2.4%

3.6%

98%

96%

94%

2%

4%

6%

2.4 Costs
2.4.1 Drug Acquisition Costs
Costs were estimated from the private payer perspective and only considered direct medical and
drug acquisition costs. Productivity loss costs and indirect costs were not considered.
Patients who received treatment incurred drug acquisition costs based on their dosing
regimens per the prescribing information or the recommended doses suggested by clinical trials.
The dosage regimen for immunosuppressant agents can differ considerably depending on many
factors, including the severity of the patient's disease, patient's weight, and other medical
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conditions that the patient may have.39 For cyclosporine A, cost estimate has been made based on
the most effective dosage regimen assessed in a body-weight–independent dosing clinical trial.72
The dosage regimen for methotrexate was based on the most common dose used for adult
patients with moderate-to-severe AD.73 There is insufficient data regarding the optimal
mycophenolate mofetil dose or the duration of therapy for adults with moderate-to-severe AD.39
However, typical starting dose in dermatology of mycophenolate mofetil was used to for cost
estimate.74 The AAD has stated that the range of azathioprine is still unknown among patients
with moderate-to-severe AD.39 Although, we estimated the cost for azathioprine acquisition
based on an average weight of ~ 70 kilograms (kg).39
Patients treated with dupilumab or upadacitinib incurred drug acquisition costs based on
dosing regimens as described in the prescribing information.75,76 For patients treated with
dupilumab, additional drug acquisition costs were incurred for the treatment loading dose for
newly diagnosed moderate-to-severe AD patients each year. For the remainder of the treated
population, the drug acquisition costs were only incurred based on the maintenance dosing
regimen. Table 3 provides the dosage regimen and the total annual costs per patient.
For cyclosporine A and mycophenolate mofetil, the annual acquisition costs were based
on the average wholesale prices (AWPs) and discounted by 22% to estimate the wholesale
acquisition costs (WACs).77,78 All other treatments were based on the WACs for their annual
costs.79–82 Annual costs were calculated by multiplying the estimated annual treatment doses
required by the treatment cost per dose. Co-pay and co-insurance were not considered. All costs
were adjusted to 2022 U.S. dollars using the Consumer Price Index (CPI).83 Table 4 provides the
annual drug acquisition costs based on population estimates.
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Table 3. Dosage Regimen and Annual Total Costs Per Patient
Dosage Form Unit Cost
($)

Units Per
Year

AWP Per Patient
Per Year ($)

WAC Per Patient
Per Year ($)

Cyclosporine Aa
Dose size 300 mg/day

100 mg ($9.18)
25 mg ($2.30)

730
1446

$6,701
$3,358
= $10,059

$5,227
$2,619
= $7,846

Methotrexate b
Dose size 15 mg/week

15 mg/0.4 ml ($706.22)

12

-

$8,475

Mycophenolate mofetil c
Dose size 250 mg/twice
daily

250 mg ($9.26)

730

$6,760

$5,273

Azathioprine d
Dose size 150 mg/day

100 mg ($9.19)
50 mg ($8.34)

365
365

-

300 mg/2 ml ($3,331.53)

1f
12

-

$3,332
$39,978
= $43,310

15 mg ($189.04)

365

-

$69,000

Treatment

Dupilumab e
Dose size 300 mg/every two
weeks
Upadacitinib g
Dose size 15 mg/day

$3,354
$3,044
= $6,398

WAC, wholesale acquisition cost; mg, milligram; ml, milliliter
a
Standard dose in adults with atopic dermatitis was estimated as 150-300 mg/day. The body-weight–independent
dosing regimen of 300 mg/day was more effective than 150 mg/day.72
b
Maintenance dose was estimated as 7.5-25 mg/week, and the most often dose used in adults was 15 mg/week.73
c
Typical starting dose used in dermatology was estimated as 250 mg twice daily.74
d
Cost was assumed based the dosage regimen of 150 mg per day (weight-based dosing assumes a ~ 70 kg patient as
an average weight).39
e
Recommended loading dose of 600 mg, followed by 300 mg given every other week.75
f
Additional drug acquisition cost was incurred for the treatment loading dose for new patients each year.75
g
Recommended dose was estimated as 15 mg daily for patients aged 18-64 years old.76

30

Table 4. Annual Drug Acquisition Costs Based on Population Estimates a,b
Treatment

Current year

Year-1

Year-2

Year-3

Current environment (scenario 1)
Cyclosporine A

Number of patients:
Costs:

361
$2,830,470

355
$2,786,404

349
$2,741,882

344
$2,696,900

Methotrexate

Number of patients:
Costs:

721
$6,114,249

710
$6,019,060

699
$5,922,885

687
$5,825,717

Mycophenolate
mofetil

Number of patients:
Costs:

180
$951,022

178
$936,216

175
$921,256

172
$906,143

Azathioprine

Number of patients:
Costs:

180
$1,154,082

178
$1,136,115

175
$1,117,961

172
$1,099,621

Dupilumab c

Number of patients:
Costs:

2164
$86,530,282

2131
$85,215,240

2097
$83,853,633

2062
$82,477,968

New environment (scenario 2)
Number of patients:
0
72
146
219
Costs:
$0
$5,000,667
$10,046,560
$15,137,985
a
Costs were based on the wholesale acquisition costs (WACs); co-pay and co-insurance were not included.
b
All costs were adjusted to 2022 United States (U.S.) dollars using the Consumer Price Index (CPI).83
c
Includes the number of patients new to treatment who received loading dose.
Upadacitinib

2.4.2 Other Costs
Based on the recommended dosing regimens for the applicable treatments, costs for
administering treatments to patients were incurred. SC injections of methotrexate and dupilumab
were administered at the clinic for the first visit by the physician and self-administered thereafter
for new patients each year. All other treatments were administered orally and thus did not incur
administration costs. The cost of SC injections was calculated based on the Physician Fee
Schedule using Current Procedural Terminology (CPT) code.84 The annual number of injections
each year was multiplied by the associated unit cost per injection to calculate the annual costs of
injection per patient.
For new treatment monitoring, all AD patients should be referred to a dermatologist after
3 months.53 Additionally, treatment discontinuation was not explicitly modeled, so all patients
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assumed to take the same treatment for the entire year. Thus, we assumed that all treated patients
would need one clinic visits per year for disease and treatment monitoring (methotrexate and
dupilumab required an additional clinic visit for the treatment administration by the physician).
Costs per clinic visit were calculated based on the Physician Fee Schedule using CPT code for
physician visits of intermediate complexity for 30-39 minutes.84 The annual frequency of clinic
visit was multiplied by the associated unit costs to calculate annual costs of clinic visits per
patient.
In order to monitor the effects of treatments on the immune system, laboratory
testing/procedure is required at the onset of treatment and periodically afterward. Consequently,
all treated patients incurred costs for laboratory tests/procedure and patient monitoring on an
annual basis. Annual laboratory testing/procedure resource use (i.e., creatinine levels, blood urea
nitrogen, complete blood count, liver enzymes, serum lipids, magnesium, potassium, renal
functions, hemoglobin, and chest x-ray) were based on estimated laboratory regimens or number
of procedures in the prescribing information of each treatment. Costs per test or procedure were
based on the Medicare Clinical Laboratory Fee Schedule (CLFS) using CPT codes.84,85
Dupilumab does not require initial laboratory testing or ongoing lab monitoring, and thus, does
not incur laboratory testing/procedure cost. The annual frequency of laboratory testing/procedure
was multiplied by the associated unit costs to calculate annual costs of laboratory
testing/procedure per patient.
All costs were adjusted to 2022 U.S. dollars using the CPI.83 Table 5 provides the number
of resource use and the total other costs per patient per year. Table 6 provides the annual other
costs based on population estimates.
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Table 5. Other Costs Per Patient Per Year
Parameter

Cyclosporine A

Methotrexate

Mycophenolate
mofetil

Azathioprine

Dupilumab

Upadacitinib

Laboratory tests a
At the initiation of the treatment
Creatinine levels

1

BUN

1

CBC

1

1

1

Liver enzymes

1

1

1

Serum lipids

1

Mg

1

K

1

Renal function

1

1

Hemoglobin

1

Chest x-ray

1
During the treatment

Creatinine levels

5

BUN

5

CBC

5

11

17

17

3

Serum lipids

3

Liver enzymes

5

Mg

5

K

5

Renal function

5

3

5

Hemoglobin
Total costs

3
$418

$307

$185

$185

$0.00

$178

Clinic visit and treatment administration
Number of visits

1

2

1

1

2

1

Unit cost per visit b

$152

$152

$152

$152

$152

$152

Unit cost per injection c

$0

$18

$0

$0

$18

$0

Total costs

$152

$321

$152

$152

$321

$152

Total other costs

$570

$629

$337

$337

$322

$330

BUN, blood urea nitrogen; CBC, complete blood count; Mg, magnesium; K, potassium
a
Costs indicated from the Medicare Clinical Laboratory Fee Schedule (CLFS). Costs were adjusted to 2022 United
States (U.S.) dollars using the Consumer Price Index (CPI).83–85
b
We assumed a one clinic visit per year. Costs were based on the Physician Fee Schedule using Current Procedural
Terminology (CPT) code for physician visits for 30-39 minutes. The administration cost per treatment dose was
based on the Physician Fee Schedule using CPT code for subcutaneous injection.84
c
Methotrexate and dupilumab required treatment administration when starting the treatment. It was assumed a one
additional visit for these two medications for treatment administration by the physician. Oral medications do not
incur any drug administration costs; therefore, they incur only the costs of one visit.84
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Table 6. Annual Other Costs Based on Population Estimates a
Treatment

Current year

Year-1

Year-2

Year-3

Current environment (scenario 1)
Cyclosporine A

Number of patients:
Costs:

361
$180,427

355
$177,730

349
$174,890

344
$172,021

Methotrexate

Number of patients:
Costs:

721
$281,224

710
$277,613

699
$273,177

687
$268,695

Mycophenolate
mofetil

Number of patients:
Costs:

180
$60,797

178
$59,850

175
$58,894

172
$57,928

Azathioprine

Number of patients:
Costs:

180
$60,797

178
$59,850

175
$58,894

172
$57,928

Dupilumab

Number of patients:
Costs:

2164
$329,231

2131
$325,740

2097
$320,535.22

2062
$315,276.66

New environment (scenario 2)
Number of patients:
0
72
146
Costs:
$0
$20,690
$41,567
Costs were adjusted to 2022 United States (U.S.) dollars using the Consumer Price Index (CPI).83
Upadacitinib

a

219
$62,632

2.5 Model Outcomes
The budget impact analysis estimated costs based on the calculated number of moderate-tosevere AD patients treated. Costs were calculated without discounting, as recommended by the
ISPOR Task Force on Good Research Practices for budget impact models.68 For each treatment,
costs were organized by treatment acquisition costs and other costs. Other costs included
resource use costs for drug administration, laboratory testing/procedure, and clinic visits. Costs
were reported as annual total, cumulative, PMPM, PMPY, PTMPM costs. The incremental
budget impact was calculated each year by comparing the total annual costs after the introduction
of upadacitinib (year 1 through year 3) with the total annual costs for the current market without
upadacitinib.
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Two scenario analyses have been performed on the annual market uptake of upadacitinib
(1% and 3%) versus (2% in the base case). Sensitivity analysis was performed to test the
robustness of model outcomes and the uncertainty of model input data. A deterministic one-way
sensitivity analysis was conducted by varying input values for AD prevalence, moderate-tosevere AD prevalence, and treatment acquisition costs of cyclosporine A, methotrexate,
mycophenolate mofetil, azathioprine, dupilumab, and upadacitinib. Key parameters were varied
from their default values using 95% confidence intervals (CI) ranges for parameters where data
were leveraged from clinical trials (AD prevalence69 and moderate-to-severe AD prevalence16)
and ±50% for parameters with greater uncertainty (e.g., treatment acquisition costs) which was
assumed to represent a reasonable range of uncertainty of dosage variation of these treatments.
The effect of varying each input on the overall 3-year budget impact was measured, and the
results were presented in a tornado diagram.

CHAPTER 3. RESULTS
3.1 Base‐Case Analysis
For one million covered lives, it was estimated that 3607 people would be treated for moderateto-severe AD with immunosuppressant agents or dupilumab in the current year, and 16 people
would be new to treatment in the first year and the following years, which they require additional
loading dose, treatment administration, clinic visit, and initiation of treatment laboratory
testing/procedure in their first year of treatment.
The total annual costs associated with immunosuppressant agents and dupilumab were
$98.4 million for the current market without upadacitinib. Total annual costs after the
introduction of upadacitinib were $102.0, $105.5, and $109.0 million in years 1 through 3,
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respectively. Annual costs for upadacitinib ranged from $5.0 in year 1, $10.0 in year 2, and $15.2
million in year 3. The cumulative costs for upadacitinib were $30.3 million over 3 years, while
overall cumulative costs across all treatments totaled approximately $316.6 million. Of the total
costs, 99% was attributed to drug acquisition costs, while the remaining 1% of costs were
attributed to other costs including treatment administration, laboratory testing/procedure, and
clinic visits.
When comparing the market scenario with upadacitinib and the market scenario without
upadacitinib, introducing upadacitinib increased the total cost by $3.5, $7.0, and $10.5 million in
years 1 through 3, respectively, resulting in a cumulative increase of $21.1 million in years 1
through 3. The incremental PMPY costs were $3.52, $7.04, and $10.59 in years 1–3,
respectively, resulting in an increased PMPM costs of $0.29 in year 1, $0.59 in year 2, and $0.88
in year 3. The incremental PTMPM costs were $70.77, $140.72, and $210.67 in years 1–3,
respectively. The average cumulative budget impact was $7.05 PMPY, $0.59 PMPM, and
$140.72 PTMPM. Table 7 provides the base-case analysis results of the budget impact model.
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Table 7. Base-Case Results
Current year

Year-1

Year-2

Year-3

Cumulative a

Total number of patients
receiving treatment

3607

Number new to treatment

0

16

16

16

49

3607

3624

3640

3657

10920

$98,492,581

$102,015,174

$105,532,133

$109,078,814

$316,626,122

$3,010,897

$2,964,134

$2,916,771

$2,868,920

$8,749,825

$2,830,470

$2,786,404

$2,741,882

$2,696,900

$8,225,185

$180,427

$177,730

$174,890

$172,021

$524,640

$6,395,473

$6,296,673

$6,196,062

$6,094,412

$18,587,146

$6,114,249

$6,019,060

$5,922,885

$5,825,717

$17,767,662

$281,224

$277,613

$273,177

$268,695

$819,485

$1,011,819

$996,066

$980,150

$964,071

$2,940,287

$951,022

$936,216

$921,256

$906,143

$2,763,615

$60,797

$59,850

$58,894

$57,928

$176,673

$1,214,879

$1,195,965

$1,176,856

$1,157,549

$3,530,369

$1,154,082

$1,136,115

$1,117,961

$1,099,621

$3,353,697

$60,797

$59,850

$58,894

$57,928

$176,673

$86,859,513

$85,540,980

$84,174,168

$82,793,245

$252,508,393

$86,530,282

$85,215,240

$83,853,633

$82,477,968

$251,546,841

$329,231

$325,740

$320,535

$315,277

$961,552

-

$5,021,357

$10,088,126

$15,200,617

$30,310,101

-

$5,000,667

$10,046,560

$15,137,985

$30,185,211

-

$20,690

$41,567

$62,632

$124,889

Total New number of
patients receiving
treatment each year
Total annual costs b ($)
Cyclosporine A
Drug costs
Other costs

c

Methotrexate
Drug costs
Other costs

c

Mycophenolate mofetil
Drug costs
Other costs

c

Azathioprine
Drug costs
Other costs c
Dupilumab
Drug costs
Other costs

c

Upadacitinib
Drug costs
Other costs

c

Incremental budget impact versus current market ($)
Total costs

-

$3,522,594

$7,039,553

$10,586,233

$21,148,379

d

-

$3.52

$7.04

$10.59

$7.05

Total PMPM costs d

-

$0.29

$0.59

$0.88

$0.59

-

$70.77

$140.72

$210.67

$140.72

Total PMPY costs

Total PTMPM costs

d

PMPM, per member per month; PMPY, per member per year; PTMPM, per treated member per month
a
Cumulative result are the sum of results from year 1 to year 3.
b
Total annual costs include drug acquisition costs, treatment administration, laboratory testing/procedure, and clinic
visits.
c
Other costs include treatment administration, laboratory testing/procedure, and clinic visits.
d
PMPY, PMPM, and PTMPM costs are based on a one million covered lives. ‘Treated members’ includes all patients
with moderate-to-severe atopic dermatitis treated with immunosuppressant agents or dupilumab for each year. The costs
listed in the ‘Cumulative’ column are the average PMPY, PMPM, and PTMPM costs over the 3-year time horizon.
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3.2 Scenario Analysis
Using a 1% annual uptake for upadacitinib (versus 2% in the base case) resulted in a reduction of
the total costs to $2.0 $3.9, and $5.9 million (versus $3.5, $7.0, and $10.5 million in the base
case) in years 1–3, respectively. The cumulative total cost from adding upadacitinib to the
formulary decreased to $11.9 million (versus $21.1 million in the base case), and the cumulative
PMPY, PMPM, and PTMPM cost decreased to $3.99, $0.33, $70.77 (versus $7.04, $0.59, and
$140.72 in the base case) in years 1–3, respectively.
Using a 3% annual uptake for upadacitinib (versus 2% in the base case) resulted in an
increase of the total costs to $5.0, $10.0, and $15.1 million (versus $3.5, $7.0, and $10.5 million
in the base case) in years 1–3, respectively. The cumulative total cost from adding upadacitinib
to the formulary increased to $30.3 million (versus $21.1 million in the base case), and the
cumulative PMPY, PMPM, and PTMPM cost increased to $10.11, $0.84, and $210.67 (versus
$7.04, $0.59, and $140.72 in the base case) in years 1–3, respectively.
A 3% annual market uptake of upadacitinib resulted in higher impact on the private payer
budget compared to 1% and 2% annual market uptake. The 1% market uptake of upadacitinib
resulted in a less budget impact for private payers compared to 2% annual market uptake.
However, both market uptake scenarios resulted in an impact on the private payer budget with no
saving. Table 8 provides the scenario analyses results.

38

Table 8. Scenario Analyses Results
Incremental costs

Uptake

Base case
(Annual uptake of 2%)

Scenario 1
(Annual uptake of 1%)

Scenario 2
(Annual uptake of 3%)

Total costs

PMPY d

PMPM d

PTMPM d

Year-1

$3,522,594

$3.52

$0.29

$70.77

Year-2

$7,039,553

$7.04

$0.59

$140.72

Year-3

$10,586,233

$10.59

$0.88

$210.67

Cumulative a

$21,148,379

$7.04

$0.59

$140.72

Year-1

$2,001,648

$2.00

$0.17

$35.79

Year-2

$3,983,906

$3.98

$0.33

$70.77

Year-3

$5,982,037

$5.98

$0.50

$105.74

Cumulative a

$11,967,592

$3.99

$0.33

$70.77

Year-1

$5,043,539

$5.04

$0.42

$105.74

Year-2

$10,095,199

$10.10

$0.84

$210.67

Year-3

$15,190,429

$15.19

$1.27

$315.60

Cumulative a

$30,329,167

$10.11

$0.84

$210.67

PMPM, per member per month; PMPY, per member per year; PTMPM, per treated member per month
a
Cumulative result are the sum of results from year 1 to year 3.
d
PMPY, PMPM, and PTMPM costs were based on a one million covered lives. ‘Treated members’ includes all patients
with moderate-to-severe atopic dermatitis treated with immunosuppressant agents or dupilumab for each year. The costs
listed in the ‘Cumulative’ column are the average PMPY, PMPM, and PTMPM costs over the 3-year time horizon.

3.3 Sensitivity Analysis
Sensitivity analysis results were most sensitive to the treatment acquisition costs for
upadacitinib, followed by moderate-to-severe AD prevalence. AD prevalence and the acquisition
costs for dupilumab had a minimal impact. The acquisition costs for cyclosporine A,
methotrexate, mycophenolate mofetil, and azathioprine, had no impact on the incremental
budget. Nevertheless, even the reduction of 50% of the acquisition cost of upadacitinib would
still result in an impact on the private payer’s budget. Table 9 provides sensitivity analysis
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incremental cumulative total costs results. Figure 3 presents the impacts of key model parameters
on the total annual costs over 3 years.

Table 9. Sensitivity Analysis Incremental Cumulative Total Costs Results
Using
Minimum value

Using
Maximum value

Methotrexate treatment acquisition cost a

$21,435,911

$20,860,800

Cyclosporine A treatment acquisition cost a

$21,281,492

$21,015,267

Azathioprine treatment acquisition cost a

$21,202,654

$21,094,105

Mycophenolate mofetil treatment acquisition cost a

$21,193,105

$21,103,655

Dupilumab treatment acquisition cost a

$20,532,470

$21,764,295

Atopic dermatitis prevalence b

$19,853,581

$22,443,178

Moderate-to-severe atopic dermatitis prevalence c

$17,537,684

$25,086,375

Upadacitinib treatment acquisition cost a

$6,055,774

$36,240,985

Parameter

a

±50% variation of drug acquisition costs.
95% confidence interval (CI): 4.6% - 5.2%.69
c
95% confidence interval (CI): 33.90% - 46.40%.16
b

Figure 3. Sensitivity Analysis Tornado Diagram a
Budget Impact ($)

Upadacitinib treatment acquisition cost
Moderate-to-severe atopic dermatitis prevalence
Atopic dermatitis prevalence

Maximum
Minimum

Dupilumab treatment acquisition cost
Mycophenolate mofetil treatment acquisition cost
Azathioprine treatment acquisition cost
Cyclosporine A treatment acquisition cost
Methotrexate treatment acquisition cost
$0

$7,000,000

a

$14,000,000

$21,000,000

$28,000,000

$35,000,000

One-way deterministic sensitivity analysis: impact of changes of input values on the cumulative budget impact
over 3 years.
Note: drug acquisition costs were varied uniformly by ± 50% of the base-case values, while 95% confidence
intervals (CI) ranges were used for atopic dermatitis prevalence and moderate-to-severe atopic dermatitis
prevalence.
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CHAPTER 4. DISCUSSION AND LIMITATIONS
4.1 Discussion
A budget impact analysis was conducted to estimate the impact of introducing and increasing the
market share of upadacitinib to a private payer’s budget over 3 years. To our knowledge, no prior
analysis has assessed the potential budget impact of upadacitinib for the treatment of
uncontrolled moderate-to-severe AD in the U.S. The result of the analysis showed that, for the
assumed market uptake and market shares of other treatments, the introduction of upadacitinib
had a high impact on a private payer’s budget. Total costs were almost completely attributed to
drug acquisition costs rather than other costs related to treatment administration, laboratory
testing/procedure, and clinic visits. Compared with a market scenario without upadacitinib, the
total costs would increase from the first year forward after introducing upadacitinib to the market
for the treatment of uncontrolled moderate-to-severe AD. Incremental PMPY, PMPM, and
PTMPM costs increase cumulatively by $7.05, $0.59, and $140.72 over 3 years, respectively.
The results were largely driven by the differences in drug acquisition costs between upadacitinib
and the other treatments.
As a result of the low market uptake of upadacitinib and the high market share of
immunosuppressant agents and dupilumab, there was a smaller increase in total cost in the first
year of upadacitinib introduction compared with subsequent years. After the first year, there was
an increase in the annual market uptake of upadacitinib and decrease in the market share of the
other treatments. As of that, the total costs after introduction of upadacitinib increased due to the
increase of number of patients taking the new treatment in the following years.
When comparing upadacitinib with immunosuppressant agents, the drug acquisition cost
per patient per year in maintenance treatment of upadacitinib ($69,000) is considerably higher
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than the drug acquisition cost of cyclosporine A ($7,846), methotrexate ($8,475), mycophenolate
mofetil ($5,273), and azathioprine ($6,398). Both upadacitinib and immunosuppressant agents
incurred other costs related to laboratory testing/procedure, treatment administration, and clinic
visit. Cyclosporine A required more initial and ongoing laboratory tests and procedure which
resulted in higher total other costs ($570) compared to upadacitinib ($330). Methotrexate
required additional clinic visit and incur additional cost for the treatment administration, which
also resulted in higher other costs ($629) compared to upadacitinib ($330). Mycophenolate
mofetil ($337) and azathioprine ($337) incur similar other costs compared to upadacitinib
($330). However, the high acquisition cost of upadacitinib compensated for the higher other
costs of cyclosporine A and methotrexate, and thus, resulted in higher total costs when compared
to all immunosuppressant agents. Furthermore, dupilumab's drug acquisition costs ($43,310)
were higher than all immunosuppressant agents. When comparing dupilumab with upadacitinib,
dupilumab incur lower acquisition cost per patient per year ($43,310) than upadacitinib
($69,000), but the difference in drug acquisition costs between dupilumab and upadacitinib was
lower than all immunosuppressant agents and upadacitinib. Additionally, dupilumab does not
require initial or ongoing laboratory monitoring, and incur only the additional clinic visit and
treatment administration costs. The resulted total other cost of dupilumab ($322) was similar to
upadacitinib ($330) which incurred initiation and ongoing laboratory tests and clinic visit costs.
Although dupilumab has a higher acquisition cost compared to all immunosuppressant agents, a
lower acquisition cost difference from upadacitinib, and a higher market share of dupilumab
among upadacitinib and immunosuppressant agents, the incremental total costs still increased
when the number of annual upadacitinib users increased. This increase contributed to the
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increase in the total, PMPY, PMPM, and PTMPM costs during the subsequent years of
upadacitinib introduction.
Scenario analysis demonstrated that higher uptake of upadacitinib may further increase
total costs for moderate-to-severe AD, especially when market share is taken from drugs with
less expensive annual acquisition costs for maintenance treatment, such as methotrexate,
cyclosporine A, mycophenolate mofetil, and azathioprine. Both market uptake scenarios resulted
in an impact on the private payer budget. Sensitivity analysis demonstrated that the overall costs
were almost attributed to the acquisition cost of upadacitinib, followed by moderate-to-severe
AD prevalence. AD prevalence and the acquisition costs for dupilumab had a minimal impact.
There would still be an impact in the budget of private payers even if the acquisition cost of
upadacitinib was cut in half (with no saving).
While previous studies have examined the budget impact for various AD treatments, no
studies have included systemic immunosuppressant agents, dupilumab, or upadacitinib among
the treatment options for uncontrolled moderate-to-severe AD.86–88 An ICER report discussed a
budget impact analysis results of several new treatment options, including upadacitinib, and the
replacement of these options with dupilumab plus usual care (10% mix) or usual care alone
(90%) over five years. Each year, they assigned 103,200 new individuals to the new treatments.
For all prices evaluated, their analysis showed that the percentage of patients that could be
treated by the new treatments within that pre-specified budget threshold was between 8% and
79% for all prices evaluated.65 No further information was published regarding their analysis.

4.2 Limitations
The prevalence of AD and moderate-to-severe AD were assumed to remain constant over the
modelled time horizon. Recent data showed that the prevalence of AD is still increasing.89–91
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However, researchers stated that the definitions and measurements of AD have been problematic,
leading to difficulties in differentiating real changes in disease prevalence from secular changes
in diagnosis.89–91 At this point, the evidence does not support a conclusion that AD or moderateto-severe AD is increasing over time. In addition, our sensitivity analysis demonstrated that
changes in prevalence rates of AD had a minimal impact on the private payer budget. In other
words, the increase in the prevalence of AD would still result in an impact on the budget of
private payers. Furthermore, the findings from our analysis indicated that the budget impact was
largely driven by the acquisition costs associated with upadacitinib.
The age of patients with moderate-to-severe AD was not stratified in our model. Age
stratification could affect the drug dose, the number of laboratory tests, and thus, the cost
incurred for each patient. Epidemiological data for our estimates indicated however, that there is
no considerable difference in the prevalence between young and old adults, and prevalence
differs significantly only between children and adults.16,69
Considering that drug acquisition costs were based on recent WACs, individual costs
may differ depending on other treatments not considered in this analysis, such as biosimilars and
topical anti-inflammatory medications for acute flare treatment. Manufacturer discounts and
rebates can also affect drug acquisition costs. We were unable to consider discounts or rebates
since actual amounts can vary from market to market and are generally proprietary information.
A Medicare reimbursement rate was used to estimate the costs of laboratory
testing/procedure, treatment administration, and clinic visits. Since not all health care providers
are reimbursed at the same rate, and private health insurances incur higher reimbursement rates
than Medicare and Medicaid92, we chose to use the Medicare reimbursement rate because, first,
private payer reimbursement rates are negotiated privately with different providers and are
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therefore not publicly available. Second, the Medicare reimbursement rate is higher than
Medicaid reimbursement rate.93 Accordingly, laboratory testing/procedure, treatment
administration, and clinic visits were estimated using the highest reimbursement rate that is
publicly available. Our result, however, could underestimate costs incurred for laboratory
testing/procedure, treatment administration, and clinic visits.
Market shares and market landscapes may change over time in the real world as new
treatments may enter the market.47,54 Because there are no biosimilars marketed in the U.S. for
any of the treatments included in this analysis, we did not include biosimilars in our analysis.
However, the introduction of biosimilars could affect our current market share estimations.
As all immunosuppressant agents and upadacitinib have similar serious adverse event
profiles, and laboratory tests, the cost of treating serious adverse events was not taken into
account in our analysis.
This budget impact analysis did not consider treatment response and assumed 100%
adherence to therapy for each year of the modeled time horizon. If a more effective treatment
results in a decrease in health care resource use, such differences may impact costs. The use of
topical anti-inflammatory medications for acute flares management could affect the treatment
response and, therefore, adherence for those patients.94 However, patient adherence to treatments
is largely based on how many flares the patient may experience.94,95 Anti-inflammatory
medications that the patient can buy over the counter (OTC) or basic management that the
patient should follow can affect the management of the disease and treatment response, and thus,
the adherence.

45

CHAPTER 5. CONCLUSION
For the assumed market uptake and market shares, the introduction of upadacitinib had a high
impact on the U.S. private payer’s budget. The introduction of upadacitinib, with a 2% annual
uptake over 3 years, is expected to have a financial impact to the U.S. private payer budget and
thus, it may increase the cost of treating patients with moderate-to-severe AD whose disease is
not adequately controlled with topical anti-inflammatory medications. Although the results of the
scenarios were consistent, the future uptake of biosimilars and treatment adherence may affect
the overall total costs associated with treating uncontrolled moderate-to-severe AD patients.
This study is the first step in addressing the impact of upadacitinib on the U.S. private
payer’s budget. Due to upadacitinib's impact on private payer budgets, it may make it harder for
American patients to access newer treatments for moderate-to-severe AD. However, because of
the high cost of upadacitinib that resulted in an impact on the private payer’s budget, questions
may remain about the value of this new therapy. Further studies are needed to provide a more
real-world data to assess the impact of changes in essential drugs for moderate-to-severe AD
patients whose disease is not adequately controlled with topical anti-inflammatory medications
in the U.S.
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APPENDIX A
SUPPLEMENTAL INFORMATION OF CHAPTER 2
A.1 Treatment Mix (market shares and market uptake):
Parameter
Number of patients with moderate-to-severe atopic
dermatitis treated with immunosuppressant agents or
dupilumab each year

Current
year

Year-1

Year-2

Year-3

3607

3624

3640

3657

Patients with moderate-to-severe atopic dermatitis treated with systemic immunosuppressant agents
Cyclosporine A
Upadacitinib
Number of new patients who receive cyclosporine A
Number of patients who receive cyclosporine A
Number of patients who receive upadacitinib
Methotrexate
Upadacitinib
Number of new patients who receive methotrexate
Number of patients who receive methotrexate
Number of patients who receive upadacitinib
Mycophenolate mofetil
Upadacitinib
Number of new patients who receive mycophenolate
mofetil
Number of patients who receive mycophenolate mofetil
Number of patients who receive upadacitinib
Azathioprine
Upadacitinib
Number of new patients who receive azathioprine
Number of patients who receive azathioprine
Number of patients who receive upadacitinib

10.0%
0.0%
0
361
0
20.0%
0.0%
0
721
0
5.0%
0.0%

9.8%
0.2%
2
355
7
19.6%
0.4%
3
710
14
4.9%
0.1%

9.6%
0.4%
2
349
15
19.2%
0.8%
3
699
29
4.8%
0.2%

9.4%
0.6%
2
344
22
18.8%
1.2%
3
687
44
4.7%
0.3%

0

1

1

1

180
0
5.0%
0.0%
0
180
0

178
4
4.9%
0.1%
1
178
4

175
7
4.8%
0.2%
1
175
7

172
11
4.7%
0.3%
1
172
11

Patients with moderate-to-severe atopic dermatitis treated with dupilumab
Dupilumab
Upadacitinib

60.0%
0.0%
0
2164
0

Number of new patients who receive dupilumab
Number of patients who receive dupilumab
Number of patients who receive upadacitinib

58.8%
1.2%
10
2131
43

57.6%
2.4%
9
2097
87

56.4%
3.6%
9
2062
132

Total market shares of current treatments and annual uptake of upadacitinib
Market shares of immunosuppressant agents and dupilumab

100%

98%

96%

94%

Market share of updacitinib

0.0%

2.0%

4.0%

6.0%

3607

3551

3494

3437

0

0

1

1

0

72

146

219

Total number of patients who may receive all treatments
(except upadacitinib) each year
Number of new patients who receive upadacitinib
Total number of patients who may receive upadacitinib
each year based on market share
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A.2 Estimated Other Costs (laboratory test/procedure costs):
Treatments/laboratory tests or procedure
(CPT code)

Number of tests per
year

Unit cost per
tests
($)

Total costs per patient
per year
($)

Cyclosporine A
At the initiation of the treatment
Creatinine levels (CPT:82565)

1

$7.18

$7.18

BUN (CPT:84520)

1

$5.54

$5.54

CBC (CPT:85025)

1

$10.88

$10.88

Liver enzymes (CPT:80076)

1

$11.44

$11.44

Serum lipids (CPT:80061)

1

$18.75

$18.75

Magnesium (CPT:83735)

1

$9.38

$9.38

1
During the treatment

$6.44

$6.44

Creatinine levels (CPT:82565)

5

$7.18

$35.90

BUN (CPT:84520)

5

$5.54

$27.70

CBC (CPT:85025)

5

$10.88

$54.40

Liver enzymes (CPT:80076)

5

$11.44

$57.20

Serum lipids (CPT:80061)

5

$18.75

$93.75

Magnesium (CPT:83735)

5

$9.38

$46.90

Potassium (CPT:84132)

5

$6.44

$32.20

Potassium (CPT:84132)

$417.66
Methotrexate
At the initiation of the treatment
CBC (CPT:85025)

1

$10.88

$10.88

Liver enzymes (CPT:80076)

1

$11.44

$11.44

Renal function tests (CPT:80069)

1

$12.16

$12.16

Chest x-ray (CPT:71046)

1

$34.61

$34.61

During the treatment
CBC (CPT:85025)

11

$10.88

$119.68

Liver enzymes (CPT:80076)

5

$11.44

$57.20

Renal function tests (CPT:80069)

5

$12.16

$60.80
$306.77

No lab tests

Mycophenolate mofetil
At the initiation of the treatment
0
$0.00
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$0.00

CBC (CPT:85025)

During the treatment
17

$10.88

$184.96
$184.96

0

$0.00

$0.00

During the treatment
17

$10.88

$184.96
$184.96

Azathioprine
At the initiation of the treatment
No lab tests
CBC (CPT:85025)

Dupilumab
At the initiation of the treatment
No lab tests

0

$0.00

$0.00

No lab tests

During the treatment
0

$0.00

$0.00
$0.00

Upadacitinib
At the initiation of the treatment
Hemoglobin (CPT:85018)

1

$3.32

$3.32

CBC (CPT:85025)

1

$10.88

$10.88

Serum lipids (CPT:80061)

1

$18.75

$18.75

1
During the treatment

$11.44

$11.44

Hemoglobin (CPT:85018)

3

$3.32

$9.96

CBC (CPT:85025)

3

$10.88

$32.64

Serum lipids (CPT:80061)

3

$18.75

$56.25

Liver enzymes (CPT:80076)

3

$11.44

$34.32

Liver enzymes (CPT:80076)

$177.56
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A.3 Estimated Other Costs (physician visits and treatment administration costs):
Number of
visits per
year

Unit cost
per visit
($)

Number of
injections
per year

Unit cost
per
injection
($)

Total number of
visits per patient
per year

Total costs per
patient per
year ($)

Cyclosporine A
(CPT:99214)

1

$152.11

0

$0.00

1

$152.11

Methotrexate
(CPT:99214)
(CPT: 96372)

1

$152.11

1

$17.53

2

$321.75

Mycophenolate
mofetil
(CPT:99214)

1

$152.11

0

$0.00

1

$152.11

Azathioprine
(CPT:99214)

1

$152.11

0

$0.00

1

$152.11

Dupilumab
(CPT:99214)
(CPT: 96372)

1

$152.11

1

$17.53

2

$321.75

Upadacitinib
(CPT:99214)

1

$152.11

0

$0.00

1

$152.11

Treatments
(CPT code)
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APPENDIX B
SUPPLEMENTAL INFORMATION OF CHAPTER 3
B.1 Budget Impact: Annual Costs:
Cost outcomes

Current year

Year-1

Year-2

Year-3

Cyclosporine A
Drug costs

$2,830,470.11

$2,786,404.11

$2,741,881.69

$2,696,899.64

Other costs
Total cyclosporine
A costs

$180,426.72

$177,729.54

$174,889.70

$172,020.54

$3,010,896.83

$2,964,133.65

$2,916,771.39

$2,868,920.18

Methotrexate
Drug costs

$6,114,249.37

$6,019,060.04

$5,922,884.80

$5,825,716.67

Other costs
Total methotrexate
costs

$281,224.13

$277,612.64

$273,176.82

$268,695.21

$6,395,473.50

$6,296,672.69

$6,196,061.62

$6,094,411.88

Mycophenolate mofetil
Drug costs

$951,021.53

$936,215.60

$921,256.33

$906,142.62

Other costs

$60,796.98

$59,850.46

$58,894.15

$57,927.96

Total
mycophenolate
mofetil costs

$1,011,818.50

$996,066.07

$980,150.48

$964,070.58

Azathioprine
Drug costs

$1,154,082.03

$1,136,114.77

$1,117,961.42

$1,099,620.66

Other costs
Total azathioprine
costs

$60,796.98

$59,850.46

$58,894.15

$57,927.96

$1,214,879.01

$1,195,965.24

$1,176,855.57

$1,157,548.61

Dupilumab
Drug costs

$86,530,281.78

$85,215,240.12

$83,853,632.76

$82,477,968.49

Other costs

$329,231.14

$325,740.04

$320,535.22

$315,276.66

Total dupilumab
costs

$86,859,512.92

$85,540,980.16

$84,174,167.97

$82,793,245.16

Upadacitinib
Drug costs

$0.00

$5,000,666.76

$10,046,559.55

$15,137,985.14

Other costs
Total upadacitinib
costs

$0.00

$20,689.89

$41,566.90

$62,632.29

$0.00

$5,021,356.65

$10,088,126.45

$15,200,617.43

Total annual costs

$98,492,580.76

$102,015,174.45

$105,532,133.48

$109,078,813.83

Incremental budget impact versus current market
Total costs

-

$3,522,593.69
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$7,039,552.72

$10,586,233.07

B.2 Budget Impact: Per Member Per Year (PMPY):
Cost outcomes

Current year

Year-1

Year-2

Year-3

Cyclosporine A
Drug costs

$2.83

$2.79

$2.74

$2.70

Other costs

$0.18

$0.18

$0.17

$0.17

Total cyclosporine A costs

$3.01

$2.96

$2.92

$2.87

Methotrexate
Drug costs

$6.11

$6.02

$5.92

$5.83

Other costs

$0.28

$0.28

$0.27

$0.27

Total methotrexate costs

$6.40

$6.30

$6.20

$6.09

Mycophenolate mofetil
Drug costs

$0.95

$0.94

$0.92

$0.91

Other costs
Total mycophenolate mofetil
costs

$0.06

$0.06

$0.06

$0.06

$1.01

$1.00

$0.98

$0.96

Azathioprine
Drug costs

$1.15

$1.14

$1.12

$1.10

Other costs

$0.06

$0.06

$0.06

$0.06

Total azathioprine costs

$1.21

$1.20

$1.18

$1.16

Dupilumab
Drug costs

$86.53

$85.22

$83.85

$82.48

Other costs

$0.33

$0.33

$0.32

$0.32

Total dupilumab costs

$86.86

$85.54

$84.17

$82.79

Upadacitinib
Drug costs

$0.00

$5.00

$10.05

$15.14

Other costs

$0.00

$0.02

$0.04

$0.06

Total upadacitinib costs

$0.00

$5.02

$10.09

$15.20

Total PMPY costs

$98.49

$102.02

$105.53

$109.08

Incremental budget impact versus current market
Total PMPY costs

-

$3.52

52

$7.04

$10.59

B.3 Budget Impact: Per Member Per Month (PMPM):
Cost outcomes

Current year

Year-1

Year-2

Year-3

Drug costs

$0.24

$0.23

$0.23

$0.22

Other costs

$0.02

$0.01

$0.01

$0.01

Total cyclosporine A costs

$0.25

$0.25

$0.24

$0.24

Drug costs

$0.51

$0.50

$0.49

$0.49

Other costs

$0.02

$0.02

$0.02

$0.02

Total methotrexate costs

$0.53

$0.52

$0.52

$0.51

Drug costs

$0.08

$0.08

$0.08

$0.08

Other costs
Total mycophenolate mofetil
costs
Azathioprine

$0.01

$0.00

$0.00

$0.00

$0.08

$0.08

$0.08

$0.08

Drug costs

$0.10

$0.09

$0.09

$0.09

Other costs

$0.01

$0.00

$0.00

$0.00

Total azathioprine costs

$0.10

$0.10

$0.10

$0.10

Drug costs

$7.21

$7.10

$6.99

$6.87

Other costs

$0.03

$0.03

$0.03

$0.03

Total dupilumab costs

$7.24

$7.13

$7.01

$6.90

Drug costs

$0.00

$0.42

$0.84

$1.26

Other costs

$0.00

$0.00

$0.00

$0.01

Total upadacitinib costs

$0.00

$0.42

$0.84

$1.27

Total PMPM costs

$8.21

$8.50

$8.79

$9.09

Cyclosporine A

Methotrexate

Mycophenolate mofetil

Dupilumab

Upadacitinib

Incremental budget impact versus current market
Total PMPM costs

-

$0.29

53

$0.59

$0.88

B.4 Budget Impact: Per Treated Member Per Month (PTMPM):
Cost outcomes

Current year

Year-1

Year-2

Year-3

Drug costs

$65.39

$64.08

$62.77

$61.46

Other costs

$4.17

$4.09

$4.00

$3.92

Total cyclosporine A costs

$69.55

$68.17

$66.77

$65.38

Drug costs

$141.24

$138.42

$135.59

$132.77

Other costs

$6.50

$6.38

$6.25

$6.12

Total methotrexate costs

$147.74

$144.80

$141.85

$138.89

Drug costs

$21.97

$21.53

$21.09

$20.65

Other costs
Total mycophenolate mofetil
costs
Azathioprine

$1.40

$1.38

$1.35

$1.32

$23.37

$22.91

$22.44

$21.97

Drug costs

$26.66

$26.13

$25.59

$25.06

Other costs

$1.40

$1.38

$1.35

$1.32

Total azathioprine costs

$28.06

$27.50

$26.94

$26.38

Drug costs

$1,998.92

$1,959.68

$1,919.68

$1,879.69

Other costs

$7.61

$7.49

$7.34

$7.19

Total dupilumab costs

$2,006.52

$1,967.17

$1,927.02

$1,886.88

Drug costs

$0.00

$115.00

$230.00

$345.00

Other costs

$0.00

$0.48

$0.95

$1.43

Total upadacitinib costs

$0.00

$115.48

$230.95

$346.43

Total PTMPM costs

$2,275.26

$2,346.02

$2,415.98

$2,485.93

Cyclosporine A

Methotrexate

Mycophenolate mofetil

Dupilumab

Upadacitinib

Incremental budget impact versus current market
Total PTMPM costs

-

$70.77

54

$140.72

$210.67

B.5 Sensitivity Analysis:
Parameter
Atopic dermatitis prevalence
Moderate-to-severe atopic dermatitis
prevalence
Upadacitinib treatment acquisition cost
Cyclosporine A treatment acquisition
cost
Dupilumab treatment acquisition cost
Methotrexate treatment acquisition cost
Mycophenolate mofetil treatment
acquisition cost
Azathioprine treatment acquisition cost

Base Case

Variation

Minimum

Maximum

4.90%

95% CI

4.60%

5.20%

40%

95% CI

33.90%

46.40%

$69,000

±50%

$34,499.80

$103,499.40

$7,846.33

±50%

$3,923.17

$11,769.50

$43,310

$21,655.00

$64,965.00

$8,475

±50%
±50%

$4,237.50

$12,712.50

$5,273

±50%

$2,636.32

$7,908.96

$6,398

±50%

$3,199.23

$9,597.68
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